Scholarlink

<p>Engineered heart muscle (EHM) is formulated as surgically transplantable, contractile “heart patches” for the remuscularization of the heart in advanced heart failure. We tested whether epicardial EHM allografts composed of induced pluripotent stem cell–derived cardiomyocytes and stromal cells can structurally and functionally support the failing heart in rhesus macaques without limiting side effects such as arrhythmia or tumor formation. After demonstration of the feasibility of rhesus EHM production, we observed a&#xa0;dose-dependent remuscularization of the rhesus macaque heart for up to 6&#xa0;months after EHM transplantation. In a&#xa0;newly developed heart failure model EHM transplantation was associated with improved target heart wall contractility and signals of enhanced global function (ejection fraction). Histopathology and gadolinium-based perfusion magnetic resonance imaging (MRI) confirmed cell retention and functional vascularization. No EHM-related arrhythmia or tumor growth was observed. These feasibility, safety and efficacy data provided the basis for approval of a&#xa0;first-in-human clinical trial on tissue-engineered heart repair. Clinical data obtained from one patient confirmed the data on remuscularization after EHM implantation in advanced-stage heart failure.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bioartifizielles Myokard für die Herzreparatur

  • 期刊论文

  • 发表日期：

    2026年6月16日

查看全文
  • Ahmad Fawad Jebran,
  • Tim Seidler,
  • Malte Tiburcy,
  • Manuel J. Santander,
  • Felix Bremmer,
  • Susann Boretius,
  • Rabea Hinkel,
  • Stefan Ensminger,
  • Ingo Kutschka,
  • Wolfram Zimmermann

摘要

Engineered heart muscle (EHM) is formulated as surgically transplantable, contractile “heart patches” for the remuscularization of the heart in advanced heart failure. We tested whether epicardial EHM allografts composed of induced pluripotent stem cell–derived cardiomyocytes and stromal cells can structurally and functionally support the failing heart in rhesus macaques without limiting side effects such as arrhythmia or tumor formation. After demonstration of the feasibility of rhesus EHM production, we observed a dose-dependent remuscularization of the rhesus macaque heart for up to 6 months after EHM transplantation. In a newly developed heart failure model EHM transplantation was associated with improved target heart wall contractility and signals of enhanced global function (ejection fraction). Histopathology and gadolinium-based perfusion magnetic resonance imaging (MRI) confirmed cell retention and functional vascularization. No EHM-related arrhythmia or tumor growth was observed. These feasibility, safety and efficacy data provided the basis for approval of a first-in-human clinical trial on tissue-engineered heart repair. Clinical data obtained from one patient confirmed the data on remuscularization after EHM implantation in advanced-stage heart failure.